SCHEMBL18175986

SCHEMBL18175986

Nc1cc(C(=O)N2CCOCC2)ccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
GABRP O00591 1/20 0.53
GABRD O14764 1/20 0.53
GABRA1 P14867 1/20 0.53
GABRB1 P18505 1/20 0.53
GABRG2 P18507 1/20 0.53
GABRB3 P28472 1/20 0.53
GABRA5 P31644 1/20 0.53
GABRA3 P34903 1/20 0.53
GABRA2 P47869 1/20 0.53
GABRB2 P47870 1/20 0.53
GABRA4 P48169 1/20 0.53
GABRE P78334 1/20 0.53
GABRA6 Q16445 1/20 0.53
GABRG1 Q8N1C3 1/20 0.53
GABRG3 Q99928 1/20 0.53
GABRQ Q9UN88 1/20 0.53
HPGD P15428 5/20 0.52
PHGDH O43175 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14858253 0.85 HPGD (0.62) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5338061 0.84 HPGD (0.65) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3875051 0.83 SMN1; SMN2 (0.56) PKMSMN1; SMN2HPGDPHGDHALDH1A1
SCHEMBL6179799 0.83 GABRP (0.59) SMN1; SMN2GABRPGABRDGABRA1GABRB1
SCHEMBL3249195 0.81 PKM (0.63) PKMSMN1; SMN2HPGDPHGDHALDH1A1
SCHEMBL3295635 0.81 PKM (0.55) PKMSMN1; SMN2HPGDPHGDHALDH1A1
SCHEMBL17689077 0.81 HPGD (0.60) PKMSMN1; SMN2HPGDPHGDHALDH1A1
SCHEMBL28226884 0.81 MEN1 (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3875054 0.81 PKM (0.51) PKMSMN1; SMN2HPGDPHGDHALDH1A1
SCHEMBL20867961 0.79 PKM (0.52) PKMSMN1; SMN2HPGDPHGDHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346764-A1 Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors ALKAHEST, INC. 2023-11-02 US disclosed
EP-2417120-B1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346764-A1 Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors CCR3, CCR1, CCR4 PKM 4061/4885SMN1; SMN2 3606/4885GABRP 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.